



Differentiation and adaptation of Natural Killer cells for anti-malarial immunity

Journal:	<i>Immunological Reviews</i>
Manuscript ID	IMR-2019-048
Manuscript Type:	Invited Review
Date Submitted by the Author:	02-Aug-2019
Complete List of Authors:	Goodier, Martin; London School of Hygiene and Tropical Medicine, Department of Infection Biology Wolf, Asia-Sophia; University College London, Department of Infection and Immunity Riley, Eleanor; The University of Edinburgh
Keywords:	Natural Killer Cells < Cell Lineages and Subsets, malaria, Antibodies < Molecules, Cytokines < Molecules, adaptive immunity

Differentiation and adaptation of Natural Killer cells for anti-malarial immunity

Martin R. Goodier¹, Asia-Sophia Wolf^{1,2} and Eleanor M Riley^{1,3}

¹Department of Infection Biology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom. Tel. 0044 612 7934; Fax. 00 44 207 637 4314

²Department of Infection and Immunity, University College London, London WC1E 6JF, United Kingdom. Tel. 0044 203 108 2351

³The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, United Kingdom. Tel. 0044 131 651 7320

Corresponding Authors:

Martin R Goodier: martin.goodier@lshtm.ac.uk

Eleanor M. Riley. Eleanor.riley@roslin.ed.ac.uk

1
2
3 **Running Header**
4
5

6 NK cell adaptation for anti-malarial immunity
7

8
9 **Key words**
10

11 Natural Killer cells, malaria, antibodies, cytokines, adaptive immunity
12
13

14
15
16
17
18
19
20 **Abstract**
21

22 Natural killer cells employ a diverse arsenal of effector mechanisms to target intracellular pathogens.
23
24 Differentiation of NK cell activation pathways occurs along a continuum from reliance on innate pro-
25
26 inflammatory cytokines and stress-induced host ligands through to interaction with signals derived
27
28 from acquired immune responses. Importantly, the degree of functional differentiation of the NK cell
29
30 lineage influences the magnitude and specificity of interactions with host cells infected with viruses,
31
32 bacteria, fungi and parasites. Individual humans possess a vast diversity of distinct NK cell clones,
33
34 each with the capacity to vary along this functional differentiation pathway, which - when combined
35
36 - results in unique individual responses to different infections. Here we summarise these NK cell
37
38 differentiation events, review evidence for direct interaction of malaria-infected host cells with NK
39
40 cells and assess how innate inflammatory signals induced by malaria parasite-associated molecular
41
42 patterns influence the indirect activation and function of NK cells. Finally, we discuss evidence that
43
44 anti-malarial immunity develops in parallel with advancing NK differentiation, coincident with a loss
45
46 of reliance on inflammatory signals, and a refined capacity of NK cells to target malaria parasites
47
48 more precisely, particularly through antibody-dependent mechanisms.
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Natural killer (NK) cells were initially identified as cytotoxic effector cells which recognise cancers in the context of 'missing self' – a process involving the absence or down regulation of self MHC molecules on tumor cells and which was subsequently observed in the recognition of virus-infected host cells^{1,2}. NK cells are now recognised as a phenotypically diverse population of innate lymphoid cells expressing a vast array of surface receptors that regulate their function³. Whilst much of this heterogeneity relates to individual and population level genetic diversity, environmental factors have a considerable impact on the functional phenotype of NK cells³⁻⁵. Age and the extent of exposure to infectious agents (particularly persistent viruses) can independently modulate the functional diversification of NK cells⁶⁻⁹.

Differences in the mode of activation of NK cells impact directly on how these cells are able to integrate immune activating signals resulting from malaria infection. Broadly speaking, less differentiated NK cells have increased reliance on innate inflammation-associated signals for their activation whilst age- and infection-related differentiation promotes integration of NK cell function with adaptive immune signals.

Evidence from experimental malaria infections in mice, humanised mouse models and controlled human malaria infections suggests NK cells are integral to the early immune response and are activated by inflammatory cytokines induced by blood stage infection. However, whilst affording some degree of protection against infection, NK cells can in some circumstances contribute to a pathogenic inflammatory cascade associated with symptomatic disease (reviewed in^{10,11}). Conversely, lesser reliance on inflammatory mediators alongside the coordinated maturation of the NK cell compartment and broadening of acquired malaria antigen-specific immunity may enhance protection against both malaria infection and malarial disease^{10,11}. By integrating innate cytokine-mediated pro-inflammatory signals with adaptive immune signals induced by malaria parasites themselves, NK cells can act both as sensors of malaria infection and effectors of malaria specific anti-parasite immunity.

1
2
3 67 Malaria is predominantly a blood-borne disease with growth and replication of asexual parasites and
4
5 68 differentiation of transmissible (sexual) stages (gametocytes) occurring in the peripheral circulation,
6
7 69 spleen and bone marrow. The interaction of malaria-infected cells with circulating peripheral blood
8
9 70 NK cells is thus of potential relevance. However, the initial stage of the infection occurs in the liver
10
11 71 where parasite-infected cells may also encounter tissue resident immune cells.
12
13

17 73 **Human natural killer cell differentiation**

18
19

20 74 In humans, peripheral blood NK cells are defined according to the expression of CD56 (N-CAM) and
21
22 75 the lack of CD3 ϵ chain. Peripheral blood NK cells express variable levels of CD56 – CD56^{bright} cells
23
24 76 being a minor population (circa 10% of peripheral blood NK cells) and CD56^{dim} being the majority
25
26 77 subset. In the blood, CD56^{bright} NK cells are regarded as the least differentiated subset although a
27
28 78 direct precursor relationship with CD56^{dim} NK cells has not been definitively established. A schema
29
30 79 representing the current understanding of human blood NK cell phenotypic and functional
31
32 80 differentiation is shown in *Figure 1*¹². Importantly, CD56^{dim} blood NK cells represent a spectrum of
33
34 81 NK cell differentiation – a subset of CD56^{dim} cells also express high levels of CD57, a cell surface
35
36 82 moiety also associated with advanced T cell differentiation and senescence¹³ (*Figure 1*).
37
38 83 Interestingly, whilst CD56^{bright} cells have longer telomeres and higher telomerase activity than the
39
40 84 highly differentiated CD56^{dim}CD57⁺ subset, irrespective of age, NK cells of all subsets from younger
41
42 85 individuals tend to have longer telomeres than NK cells of older individuals, indicating that the
43
44 86 differentiation status of NK cells is only partly age-related¹⁴. Equivalent functional differentiation of
45
46 87 NK cells is observed in mice and non-human primates, which may be of relevance to malaria
47
48 88 infection models¹⁵.
49
50

51
52 89 Progressive differentiation is associated with phenotypic changes which impact the functional
53
54 90 propensities of NK cells (*Figure 1*). CD56^{bright} cells are characterised by their high level expression
55
56 91 of cytokine receptors – in particular those for IL-12, IL-18, the innate common gamma-chain
57
58 92 cytokines, and notably the CD25-CD122 heterodimer which possesses high affinity for interleukin-2
59
60 93 (which enables NK cells to respond to picomolar concentrations of this T cell-derived cytokine)^{12,16}.

1
2
3
4 CD56^{dim} NK cells do, however, also express intermediate levels of receptors for interferon alpha and
5
6 IL-18. Receptors for other cytokines, including IL-2, are upregulated upon activation, consistent with
7
8 additional regulation of cytokine responsiveness with increasing NK cell differentiation ¹⁷⁻¹⁹.
9
10 However, the most differentiated NK cells exhibit altered transmembrane and intracellular signalling
11
12 capacity, leading to reduced overall expression of cytokine receptors and a diminishing reliance on
13
14 both IL-12 and IL-18-mediated activation (see below).
15

16
17 Variation in expression of receptors for various stress-induced and self-recognition (MHC) ligands
18
19 also occurs with advancing NK cell differentiation (Reviewed in ¹²). CD56^{bright} NK cells express high
20
21 levels of the natural cytotoxicity receptors (NCR) NKp30 and NKp46, activating receptors of the Ig
22
23 superfamily that promote interactions of NK cells with accessory cells and have been implicated in
24
25 interactions with soluble molecules such as complement factor P and viruses, including reoviruses
26
27 ²⁰⁻²³. These less differentiated NK cells tend to express the inhibitory c-type lectin-like receptor
28
29 NKG2A, which, in conjunction with CD94, recognises HLA leader peptides bound to HLA-E (*Figure*
30
31 1). As differentiation proceeds towards a CD56^{dim}CD57⁺ phenotype, surface expression of NCRs
32
33 diminishes in parallel with an increase in the frequencies of cells expressing killer immunoglobulin-
34
35 like receptors (KIR) for MHC class I; at the same time NK cells expressing CD94-NKG2C begin to
36
37 predominate over those expressing CD94-NKG2A ¹² (*Figure 1*). Importantly, whilst only a minor
38
39 subset of CD56^{bright} NK cells express CD16, the low affinity IgG Fc receptor (FcγRIII), this receptor
40
41 is expressed on the majority of CD56^{dim} cells with expression levels being highest on CD56^{dim}CD57⁺
42
43 NK cells ¹⁹ (*Figure 1*).
44

45
46 The distribution and diversification of NK cell subsets vary considerably between blood, secondary
47
48 lymphoid tissues, and inflamed non-lymphoid tissues, which may have consequences for local anti-
49
50 pathogen responses ^{15,24}. In the spleen and secondary lymphoid tissues, including tonsils and lymph
51
52 nodes, NK cells have a less differentiated phenotype, typically CD56^{bright} c-kit⁻ IL-7R⁻ ^{25,26}. NK cells
53
54 from these secondary lymphoid tissues produce cytokines such as IFN- γ but can be induced by
55
56 cytokines such as IL-12 and IL-18 to acquire receptors such as KIR (conventionally associated with
57
58 more differentiated NK cell phenotypes), indicating that these tissue resident NK cells may be
59
60

1
2
3 actually be more differentiated than their circulating counterparts. In non-lymphoid tissues, there is
4
5 significant diversity in NK cell populations²⁴ including circulating non-resident conventional NK cells
6
7 (cNK) that are phenotypically similar to CD56^{dim} and CD56^{bright} cells, and tissue resident NK cells (Tr-
8
9 NK) that vary markedly in phenotype and function between tissues. In the liver, for example, Tr-NK
10
11 cells express CXCR6 and CD49d but are CD56^{dim} with variable KIR and NKG2C expression. In
12
13 contrast, uterine NK cells are CD56^{bright} but also bear some hallmarks of conventional CD56^{dim} NK
14
15 cells including NKG2C and KIR expression²⁷. A common feature of Tr-NK cells, however, is a lack
16
17 of expression of CD16 and CD57, typically found on cNK cells²⁴.
18
19
20
21

22 23 **Genetic and environmental factors influencing NK cell differentiation and function.** 24

25
26 As with the T and B lymphocyte compartments, there is persuasive evidence that both genetic and
27
28 environmental factors influence NK cell differentiation and function. Genetic heterogeneity, including
29
30 population diversity of both HLA and KIR gene alleles, has considerable impact on NK cell function.
31
32 NK cell responsiveness to cytokines, target cells and antibody complexed to FcR is also intrinsically
33
34 regulated by a process termed 'education', where increased functional capacity is associated with
35
36 binding of NK cell receptors to their "cognate" ligands^{28,29}. Educating signals include those
37
38 generated by interaction of inhibitory self-KIR with conventional MHC class I molecules, NKG2A with
39
40 HLA-E or HLA-G, or invariant NK cell receptors with their relevant ligands (for example the CD2-
41
42 LFA-3 interaction or CD16 crosslinking by IgG antibodies)²⁸⁻³⁰, and can be cumulative. For example,
43
44 the number of cognate pairs of KIR receptors able to bind to class I MHC molecules determines the
45
46 overall capacity for NK cell IFN- γ production and degranulation²⁹. The molecular basis for
47
48 potentiation of NK cell function by education has recently been reported to involve remodelling of
49
50 secretory lysosomes, potentially by enhanced Ca²⁺ signalling from acidic cytoplasmic intracellular
51
52 stores³¹. If so, even though infected red blood cells essentially lack MHC class I molecules,
53
54 individual genetic variation in NK cell receptors and their licensing ligands will influence the intrinsic
55
56 capacity of NK cells to mount effector responses to infection, including to blood stage malaria
57
58 parasites and may, in part, explain reported associations between KIR–HLA ligand pairings and
59
60

1
2
3 148 susceptibility to severe or cerebral malaria.^{32,33}. Recent studies on the role of *P. vivax*-infected
4
5 149 reticulocyte MHC class I expression in cytotoxic T lymphocyte responses, however, raise the
6
7 150 possibility of direct modulation of NK cell responses under certain conditions ³⁴.
8
9

10 151 Human cytomegalovirus (HCMV) infection is the most well defined driver of NK cell functional
11
12 152 diversification ^{4,8,35}. Phenotypic and functional differentiation progresses more rapidly in those with
13
14 153 HCMV infection, with increased expression of various activating and inhibitory receptors compared
15
16 154 to uninfected individuals ^{4,8,35}. More differentiated cells, including CD56^{dim}CD57⁺ subsets, are
17
18 155 increased in frequency in HCMV+ compared to HCMV- individuals ^{35,36}. Moreover, expansions of
19
20 156 cells expressing NKG2C, a differentiation-associated receptor which recognises HCMV-infected
21
22 157 host cells in the context of HLA-E binding peptides from the viral UL40 gene, are observed in HCMV+
23
24 158 individuals during natural infection or upon virus reactivation after bone marrow transplantation. ³⁶⁻³⁸
25
26
27 159 It is, however, as yet unclear whether NKG2C-HLA-E/UL40 interactions actually drive NK cell
28
29 160 differentiation or act to expand already-differentiated cells.
30
31

32 33 34 35 162 **PLZF – a master regulator of natural killer cell adaptation**

36
37 163 NK cell differentiation and functional diversification is further amplified by variation in components of
38
39 164 the signalling cascades associated with cell surface receptors ⁹. The transmembrane adaptor
40
41 165 proteins CD3 ζ and ZAP-70, and the intracellular adaptor protein SAP, define TCR $\alpha\beta$ ⁺ and TCR $\gamma\delta$ ⁺
42
43 166 T cell lineages, whilst CD19⁺ B cells are defined by expression of SYK tyrosine kinases and
44
45 167 peripheral blood monocytes by the adaptor protein Fc ϵ R1 γ , SYK and the intracellular adaptor EAT2.
46
47 168 At a population level, peripheral blood NK cells express all of these molecules although there are
48
49 169 differences in their expression between CD56^{bright} and CD56^{dim} NK cells and, more importantly,
50
51 170 between individuals infected with HCMV and uninfected individuals ⁹. In HCMV-infected individuals,
52
53 171 epigenetic suppression of the promoter of the proteomyeloid zinc finger molecule (PLZF), encoded
54
55 172 by the ZBTB16 locus, leads to down-regulation of a cassette of genes expressed in less-
56
57 173 differentiated canonical NK cells ⁹. When released from the influence of these PLZF-regulated
58
59 174 genes, the activation pathways of 'adaptive' NK cells diverge, downregulating intracellular signalling

1
2
3 175 components associated with myeloid and B cell lineages and freeing up the activity of adaptor
4
5 176 proteins typically associated with memory T cell signalling, including CD3 ζ , ZAP70 and SAP ^{7,9}. NK
6
7 177 cell adaptation results in two particular functional consequences. Firstly, enhanced signalling
8
9 178 through CD3 ζ promotes more efficient activation of NK cells via CD16, thereby promoting improved
10
11 179 activation and targeting of HCMV-infected target cells via antibody dependent pathways ^{7,9}. Although
12
13 180 adaptive NK cells are predominantly found in HCMV-infected individuals, preferential expansion of
14
15 181 Fc ϵ R1 γ - NK cells by antibody crosslinking of CD16 is observed in response to other pathogens
16
17 182 including influenza-infected target cells ⁷. A second functional consequence of NK cell adaptation is
18
19 183 a loss of expression of cytokine receptors and associated signalling components, resulting in near
20
21 184 complete loss of STAT4/p38 MAP kinase activation and inability to produce IFN- γ upon stimulation
22
23 185 with these cytokines ⁹. Taken together, these major adaptations within the blood NK cell
24
25 186 compartment, especially in HCMV-infected individuals, are likely to have important influences on NK
26
27 187 cell responses to a range of pathogens, including malaria parasites.

28
29 188 Less differentiated (canonical) NK cells that respond exclusively to cytokines and antibody-
30
31 189 responsive 'adaptive' NK cells are polar opposites on a spectrum of activation requirements.
32
33 190 Individuals differ in their frequencies of canonical and adaptive NK cells depending on their genetic
34
35 191 make-up, age, HCMV infection and exposure to other infections, but, in many individuals, cells at an
36
37 192 intermediate stage of differentiation tend to predominate. NK cells at the intermediate stage of
38
39 193 differentiation will frequently integrate signals both from innate cytokines and cell surface ligands,
40
41 194 including antigen-antibody complexes. NK cells at an intermediate stage of differentiation
42
43 195 (CD56^{dim}CD57⁺/PLZF⁺) retain residual capacity to respond to cytokines and CD56^{dim}CD57-PLZF⁺
44
45 196 NK cells have intermediate levels of both cytokine receptors and FcRs, thereby integrating both of
46
47 197 these signals (see Figure 1). Indeed, inflammatory cytokines, in particular IL-18, synergise with
48
49 198 antibody-dependent signals to activate CD56^{dim}CD16⁺ NK cells and for tumour cell targeting by
50
51 199 adaptive NK cells ^{18,39}. In summary, the extent to which the NK cells of any given person have
52
53 200 differentiated across this spectrum could, at one extreme, mean that NK cells act primarily as
54
55 201 sensors of malaria-induced pro-inflammatory signals and contribute to the malaria induced
56
57
58
59
60

1
2
3 202 inflammatory cascade; at the other end of this spectrum, NK cells mediate very effective antibody-
4
5 203 dependent cellular cytotoxicity (ADCC), thereby contributing to protective immunity whilst limiting
6
7 204 exacerbation of inflammatory processes. In practice, this implies that NK cell responses to malaria
8
9 205 may vary between individuals and over an individual's life course, with very different implications for
10
11 206 their role in protection or pathogenesis.

13 14 207 15 16 17 208 **Malaria parasite induction of the inflammatory cascade and NK cell activating cytokines**

18
19
20 209 Numerous studies of malaria infection in both animal models and humans have described the
21
22 210 induction of inflammatory and anti-inflammatory cytokines as being crucial to determining the
23
24 211 severity of disease and eventual outcomes. Erythrocytic stages of the parasite are most strongly
25
26 212 associated with the induction of inflammatory cytokines, including the NK cell-activating cytokines
27
28 213 IL-12, IL-18 and type 1 interferons.

29
30
31 214 Over the past decade, an increasing number of malarial pathogen- or danger-associated molecular
32
33 215 patterns (PAMPs and DAMPs) have been identified alongside their myeloid accessory cell receptors;
34
35 216 these interactions drive the production of a diverse array of pro- and anti-inflammatory cytokines,
36
37 217 including those modulating NK cell activity. Malaria-derived DAMPs and PAMPs include nucleic
38
39 218 acids and by-products of intraerythrocytic growth and replication including GPI anchor domains from
40
41 219 malarial proteins and modified haemozoin (reviewed in ⁴⁰). Binding of these molecules to an array
42
43
44 220 of innate recognition receptors, including TLR9, TLR7 and MyD88, has been implicated in the
45
46 221 induction of IL-18, IL-12 and IFN- α in human and murine myeloid cells ^{41,45}. For example, *P.*
47
48 222 *falciparum*-infected red blood cells (iRBC) have been shown to induce IL-18 in murine monocytes *in*
49
50 223 *vitro* and stimulation of murine bone marrow-derived myeloid dendritic cells from TLR9 or MyD88
51
52 224 knockout mice revealed an essential role for these pathways in the IL-12 response to *P. falciparum*
53
54 225 iRBC and to parasite DNA-protein or DNA-carbohydrate polymer complexes ^{41,45}. Interestingly, in
55
56 226 murine *P. yoelii* infection, production of IL-18 is MyD88-dependent but TLR9 independent, and
57
58 227 serum IL-12 increased in TLR9^{-/-} mice coincident with a downregulation of IL-10 production ⁴², whilst
59
60 228 production of IFN- α requires STING-mediated detection of parasites by macrophages ⁴⁴. These

1
2
3
4 data are therefore indicative of a complex interaction between inflammatory and anti-inflammatory
5
6 cytokines which could impact the overall NK cell response. Significantly, the AT-rich stem loops
7
8 prevalent in *P. falciparum* DNA have been implicated in TLR-9 independent recognition by the
9
10 STING, TBK1 and IRF3-IRF-7 pathways ⁴⁶ and TLR7-MyD88-mediated recognition of *P. yoelii* DNA
11
12 is implicated in the activation of plasmacytoid DCs ⁴⁴.

13
14
15 Inflammasome-mediated induction of inflammatory cytokines, in particular IL-1 β and IL-18, has also
16
17 been described during malaria infections: *P. berghei* genomic DNA complexed to normally inert
18
19 malarial hemozoin activates bone marrow-derived murine macrophages via TLR-9, providing
20
21 priming and activation signals for NLRP3/AIM2 inflammasomes ^{47,48} and circulating immune
22
23 complexes containing *P. falciparum* and *P. vivax* DNA can also induce inflammasome assembly,
24
25 caspase I induction and increased production of IL-1 β and IL-18 (RNA) in human monocytes. ⁴⁹.

26
27
28 In summary, the induction of cytokines with documented potential to activate NK cells is evident in
29
30 both human and murine malaria infections and involves the co-operation of a number of distinct
31
32 molecular patterns and signalling pathways in diverse myeloid cell populations.

33 34 35 36 37 **Linking inflammatory cytokines to *P. falciparum*-induced NK cell activation**

38
39
40
41 *In vitro* studies with human cells and *in vivo* studies with animal models have all demonstrated that
42
43 NK cells are dependent upon accessory cells and inflammatory cytokines to respond to malaria
44
45 parasite iRBC. Neutralisation of IL-12 and IL-18 abrogated the NK cell IFN- γ response to *P.*
46
47 *falciparum* iRBC and schizont lysates ⁵⁰. Subsequent studies have demonstrated a requirement for
48
49 contact between primary NK cells and accessory cells implying that, in addition to accessory cell-
50
51 derived cytokines, cell contact is necessary for full activation (*Figure 2*). An array of myeloid and T
52
53 cell-derived NK cell-activating cytokines are induced by *P. falciparum* iRBC stimulation of human
54
55 PBMC, with upregulation of IL-12, IL-15 and IL-18 RNA and IL-2 and IL-12 proteins detected *in vitro*
56
57 ⁵¹. In addition to IFN- γ production, many studies have also demonstrated the induction of IL-2R α
58
59 (CD25) on the NK cell surface indicating that IL-2 from malaria specific CD4+ T cells may synergise
60

1
2
3 255 with innate cytokines in NK cell responses to iRBC ^{52,53}. Indeed, the contribution of both accessory
4
5 256 cell- and CD4⁺ T cell-derived cytokines to the NK cell response was subsequently confirmed by IL-
6
7 257 12, IL-18 and IL-2 neutralisation, anti-IFN- $\alpha\beta$ R2 and MHC class II blockade, and CD4⁺ T cell
8
9 258 depletion from PBMC cultures prior to activation with iRBC ⁵⁴. Interestingly, in this system IFN- γ
10
11 259 production from NK cells preceded that of CD4⁺ T cells, consistent with a dominant contribution of
12
13 260 NK cells to the early immune response to iRBC.
14
15

16
17 261 One feature of these *in vitro* systems is potent responses by CD56^{bright}(KIR⁻) NK cells and CD56^{dim}
18
19 262 NK cells expressing CD94-NKG2A, which is consistent with the activation of less-differentiated NK
20
21 263 cells as might be expected for cytokine-driven responses determined by the constitutive expression
22
23 264 or upregulation of the appropriate cytokine receptors ^{51,53,55}. Contact-dependent signals for NK cell
24
25 265 responses to iRBC seem to be largely restricted to the level of accessory cells where LFA-1 on NK
26
27 266 cells may promote association with cytokine-producing accessory cells via interaction with ICAM-1
28
29 267 ^{51,52} (*Figure 2*). By contrast, the need for direct contact between NK cells and iRBC is much less
30
31 268 clear.
32
33

34
35 269 Although NK cells have been shown to form stable conjugates with iRBC ^{52,53} and purified NK cells
36
37 270 respond to *P. falciparum* iRBC with a gene expression signature that is very different to that induced
38
39 271 simply by exposing them to IL-12 + IL-18 (suggesting that additional activation signals may be
40
41 272 provided by conjugate formation), ⁵⁶ there is, as yet, no convincing evidence that direct contact with
42
43 273 iRBC is essential for NK activation, and no activating (or inhibitory) receptor-ligand interactions have
44
45 274 been defined. Early reports ^{57,58} suggested a role for interaction between the Duffy binding like
46
47 275 domain DBL-1 α of *P. falciparum* erythrocyte membrane protein-1 (PfEMP-1) and the natural
48
49 276 cytotoxicity receptor NKp30 (and to a lesser extent NKp46) but have not been confirmed, although
50
51 277 an association has been observed between polymorphisms in the *NCR3* gene encoding NKp30 and
52
53 278 the frequency of mild malaria episodes ^{57,58}. Another study indicated that chondroitin sulfate modified
54
55 279 proteins on human NK cell lines can mediating binding to PfEMP-1 on the iRBC surface, but there
56
57 280 was no evidence that this led to NK cell activation ⁵². More recently, a role has been suggested for
58
59 281 *P. falciparum*-derived microvesicles containing long non-coding RNAs in direct activation of NK cells

1
2
3 282 via the cytosolic sensor MDA5⁵⁹. There is also evidence that iRBC can inhibit NK cell activation via
4
5 283 the interaction of certain *P. falciparum* RIFIN proteins with LILRB1 (also known as LIR1, LAIR1 or
6
7 284 CD85j), a lymphocyte expressed inhibitory receptor of the immunoglobulin superfamily,⁶⁰ but the
8
9 285 relevance of this – or of any other form of direct contact between NK cells and iRBC – for NK cell
10
11 286 activation or immunity to malaria is currently unclear.

12 13 14 287 15 16 17 288 **Cytokine-induced NK cell responses in murine malaria**

18
19
20 289 The inevitable limitations associated with experimental studies of human malaria mean that many of
21
22 290 our insights arise initially in animal models of malaria, especially rodent models. Murine malaria
23
24 291 models currently provide evidence for both beneficial and harmful contributions of NK cells - either
25
26 292 controlling parasite burden or contributing to pathology. It has been recognised for some time that
27
28 293 the genetic background of the host and the parasite species are important considerations influencing
29
30 294 NK cell activity in these models^{61,62}. Nonetheless, these models offer the potential for the
31
32 295 mechanistic dissection of the cytokine cascade and NK cell activation, and their contribution to the
33
34 296 anti-parasite immune response. Cytokine-activated NK cells do appear to be involved in protection
35
36 297 in acute *P. chabaudi* infection: IL-12 restores NK cell function and control of *P. chabaudi* AS
37
38 298 parasitaemia in susceptible A/J mice whereas deletion of the IL-12 gene results in severely impaired
39
40 299 IFN- γ production, increased peak parasitaemia and delayed resolution of infection in normally
41
42 300 resistant C57BL/6 mice^{63,64}. Delayed parasite clearance also occurs in IL-15-/- C57BL6 mice and is
43
44 301 associated with reduced NK cell and DC function⁶⁵. As described above for accessory cell
45
46 302 dependence in human NK cell responses, DC-NK crosstalk is critical for NK cell IFN- γ dependent
47
48 303 immunity to *P. chabaudi* in C57BL/6 mice⁶⁶. Further studies of *P. chabaudi* infection demonstrate
49
50 304 waves of NK cell activation and proliferation in the blood and spleen with NK cell numbers peaking
51
52 305 at the time of peak parasitaemia^{67,68}. IL-18-dependent induction of the high affinity IL-2R expression
53
54 306 on NK cells and their production of IFN- γ occurred earlier and with higher magnitude after infection
55
56 307 of C57/BL6 mice with non-lethal *P.yoelii* 17XL compared to the lethal *P. yoelii* M strain, consistent
57
58 308 with a protective role for cross-talk between IL-2-producing T cells and NK cells in this model⁶⁹.

1
2
309 Furthermore, control of *P.yoelii* 17XL parasitaemia and survival were both impaired in CD36-
4
510 deficient C57BL/6 mice and this was associated with decreased production of IL-12, IL-18 and IL-
6
711 1β , and subsequent decreased NK cell production of IFN- γ and TNF- α , consistent with a role for
8
912 interactions between NK cells and accessory cells in immunity ⁷⁰.

11
12
313 If *P. chabaudi* and *P. yoelii* provide evidence for a protective role of cytokine-activated NK cells in
13
14
314 controlling parasite replication and preventing death from hyperparasitaemia, *P. berghei* ANKA
15
16
315 infection in C57BL/6 mice provides a model for NK cells to contribute to severe disease with
17
18
316 reciprocal DC activation and IL-12-dependent NK cell responses being associated with severe
19
20
317 inflammation, CD8+ T cell activation and onset of experimental cerebral malaria ⁷¹. Interestingly
21
22
318 BALB/c mice, which are normally resistant to *P. berghei* ANKA, become susceptible to experimental
23
24
319 cerebral malaria when backcrossed against the C57BL/6 NKC locus, implying a role for functional
25
26
320 NK cell receptor involvement in susceptibility to disease ⁷². Other studies suggest a role for NK cells
27
28
321 in liver injury caused by *P. berghei* NK65 in C57BL/6 mice ⁷³.

29
30
31
322 The timing and magnitude of the NK cell response may however alter the course of disease in these
32
33
323 infections. For example, expansion of the NK cell population by Flt3 ligand treatment of C57BL/6
34
35
324 mice facilitates control of *P. berghei* ANKA parasitaemia and prevents the onset of experimental
36
37
325 cerebral malaria via MyD88 and IFN- γ dependent pathways ⁷⁴. More recently, a role for NK cell
38
39
40
326 regulatory function in prevention of experimental cerebral malaria was demonstrated in *P.berghei*
41
42
43 ANKA-infected C57/BL6 mice in which a therapeutic IL-15 complex induced IL-10-producing NK
44
45
428 cells ⁷⁵.

46
47
329 Further evidence for a role for NK cells during malaria infection comes from humanised mouse
48
49
330 models of *P. falciparum*. Depletion of NK cells and macrophages facilitates sporozoite infection of
50
51
331 hepatocytes and growth of liver stage *P. falciparum* in humanised mice, suggesting a role for these
52
53
332 cells in controlling pre-erythrocytic infection by an as yet undefined mechanism ⁷⁶. Similarly, *P.*
54
55
333 *falciparum* parasitaemia induces IL-12 and IFN- γ production one week post infection even in
56
57
334 NOD/SCID mice in which NK cells are the only plausible source of this IFN- γ ⁷⁷. Finally, depletion of
58
59
60

1
2
335 NK cells from immune cell optimised humanised (RICH) mice demonstrates a role for contact-
4
5336 dependent NK cell IFN- γ production in control of parasitaemia ⁷⁸.
6
7

8337 9 10 **NK cell activation during natural malaria infections**

11
12
13
143349 Many studies associate the production of pro-inflammatory cytokines, including those which can
15
16340 activate NK cells, with severe malarial disease, raising the question of whether NK cell activation by
17
18341 these pathways necessarily contributes to protective immunity in susceptible human and animal
19
20342 hosts ⁷⁹. In reality, given the heterogeneity in both functional differentiation of NK cells and
21
22343 inflammatory responses within the affected population, it is likely that the answer lies in both the
23
24344 concentrations of pro- and anti-inflammatory mediators being produced and the frequencies of
25
26345 different NK cell subsets responding to these mediators in a given individual.
27
28

29346 NK cell-activating, NK cell-derived and NK cell-modulating cytokines are all associated with the
30
31347 severity of malarial disease. For example, ratios of pro-inflammatory IL-12, IFN- γ and TNF- α to anti-
32
33348 inflammatory TGF- β and IL-10 in iRBC-stimulated whole blood were associated with protection
34
35349 against parasitaemia, clinical malaria and anaemia in a study of Ghanaian children ⁸⁰ and reduced
36
37350 concentrations of plasma TGF- β and IL-12 were associated with severe malaria and cerebral malaria
38
39351 in Thai adults and Tanzanian children ⁸¹. Interestingly, in the latter study, plasma IL-18 was found at
40
41352 higher concentrations in people with uncomplicated malaria compared to uninfected controls but IL-
42
43353 18 concentrations declined with increasing disease severity, suggesting that inflammatory mediators
44
45354 could be involved in the control of parasitaemia, thereby preventing disease ⁸¹. By contrast, studies
46
47355 in Mali and Malawi suggest a direct association between increasing plasma IL-12 concentrations
48
49356 and severe disease or cerebral malaria ^{82,83}, perhaps revealing the importance of also considering
50
51357 the role of potentially disease-modifying concentrations of anti-inflammatory cytokines. NK cell
52
53358 activation (as defined by CD69 expression) was also elevated in cerebral malaria in a related study
54
55359 ⁸³. Whilst suggestive of a role for NK cell-activating and NK cell-modulating cytokines in determining
56
57360 the outcome of malaria infections, the currently available data are far from definitive ^{80,82,84,85}. Firstly,
58
59361 few if any studies have sought to directly correlate plasma cytokine concentrations or *in vitro*

1
2
362 stimulated cytokine production with NK cell activation and function. Secondly, the vast majority of
4
5363 these studies are cross-sectional in design and therefore cannot infer causality from any of the
6
7364 associations detected. To fully understand the interplay between inflammation and NK cell
8
9365 responses and the implications of these for control of malaria infections, much more comprehensive,
10
11366 longitudinal studies are needed – including of controlled experimental human malaria infections – in
12
13367 which cellular and cytokine responses are followed over time, ideally including pre-infection and
14
15368 post-treatment time points.

372 **Evidence for early NK cell activation during controlled human malaria infections**

28
29
303 As discussed above, controlled human malaria infections (CHMI) provide an opportunity for
31
324 longitudinal studies of infections of known magnitude and duration, and the recent establishment of
33
345 CHMI protocols in a number of laboratories - in endemic as well as non endemic areas - is providing
35
366 a rich source of data on a variety of immune cells, including NK cells. Validating earlier *in vitro* studies
37
3854, infection of malaria naïve volunteers via the bites of *P. falciparum* sporozoite-infected mosquitoes,
39
40378 followed by drug cure at the onset of patent parasitaemia, increased the frequencies of both
41
42379 CD56^{bright} and CD56^{dim} NK cells producing IFN- γ , due in part to the infection-induced differentiation
43
44380 of IL-2-producing malaria-specific memory T cells which potentiate innate NK cells responses^{86,87}.
45
46381 In a rather different study, using a blood stage inoculum to initiate infection, frequencies of NK cells
47
48382 and type 1 innate lymphoid cells (ILC-1) decreased in the blood as infection progressed but rapidly
49
50383 returned to pre-infection levels after treatment, suggesting that these cells may have been activated
51
52384 to express adhesion molecules, leading to transient sequestration in peripheral tissues⁸⁸. Similar
53
54385 observations of transient lymphocyte sequestration have long been reported in children naturally
55
56386 infected with malaria⁸⁹. Whilst these data are indicative of generalised lymphocyte activation during
57
58387 blood stage malaria infection, this tissue sequestration makes it very difficult to study malaria-
59
60

1
2
388 reactive lymphocytes during acute infection since activated - and therefore putatively protective -
4
5389 cells are absent from the peripheral leukocyte population that can be sampled. This may, in part,
6
7390 explain why NK cell gene expression signatures were negatively correlated with and predicted
8
9391 protection following CHMI of individuals vaccinated with the RTS,S malaria vaccine ⁹⁰. On the other
10
11392 hand, sporozoite-induced CHMI in a group of malaria-exposed but non-immune Tanzanian adults
12
13393 markedly reduced the proportion of circulating NK cells (and, at high doses of inoculating
14
15394 sporozoites, increased the frequencies of CD8+ mucosal associated invariant T cells, or MAIT cells)
16
17395 ⁹¹. These changes persisted for several months after drug clearance of parasites, suggesting that in
18
19396 these individuals transient activation and sequestration may not explain lymphocyte dynamics ⁹¹. As
20
21397 discussed earlier, more comprehensive CHMI studies are needed to better understand the
22
23398 contribution of NK cells and other lymphocytes to malarial immunity, including *ex vivo* analysis of
24
25399 peripheral blood cell phenotype and function during acute disease and restimulation/recall response
26
27400 analysis after treatment and restoration of homeostasis.
28
29
30
31
32
33

402 **NK cells as adaptive effectors of acquired immunity to malaria.**

34
35
36
37403 There is abundant evidence from both vaccination and infection studies that NK cell function could
38
39404 be enhanced by T cell derived IL-2 ^{54,92-95} and by specific antibodies ⁹⁶⁻⁹⁹, each of which are
40
41405 hallmarks of an adaptive immune response. As discussed above, CD25 - a component of the high
42
43406 affinity receptor for IL-2 - is constitutively expressed on less differentiated human CD56^{bright} NK cells
44
45407 and is induced by activation on more differentiated CD56^{dim} NK cell subsets; CD25 is also a marker
46
47408 of activation in murine NK cells ¹⁷.
48
49

50
51409 Consistent with the ability of NK cells to integrate both innate and adaptive immune signals, IL-18
52
53410 plays a critical role in the induction of CD25 on NK cells in a number of infections, including murine
54
55411 CMV (MCMV) and murine malaria ^{17,69}. Importantly, expression of IL-18R is maintained on the
56
57412 majority of human NK cells irrespective of their differentiation state, allowing them to continue to
58
59413 respond to IL-18 ¹⁹. This is in sharp contrast to IL-12, where expression of the IL-12R β 2 chain
60
61414 declines significantly and progressively as NK cells differentiate, making them less responsive or

1
2
3
4 15 non-responsive to IL-12, which can otherwise potently synergise with IL-18 to enhance CD25
5
6 16 expression in less differentiated human NK cells ^{18,19}. However, whether more highly differentiated
7
8 17 NK cells, including both CD56^{dim}CD57+NKG2C+ and adaptive CD56^{dim}FcεR1γ-/PLZF- subsets,
9
10 18 remain sensitive to IL-2 is not yet entirely clear, although CD57+(NKG2C+/-) NK cells do have lower
11
12 19 intrinsic proliferative capacity ^{93,100} and often respond poorly to T cell-activating recall antigens ^{18,19,93}.
13
14 20 If the reliance of these NK cell subsets on IL-2 is genuinely restricted, alternative factors such as IL-
15
16 21 15 may be required for their maintenance ¹⁸.

17
18
19 22 Taking all the evidence together, it seems that as NK cells differentiate they progressively lose
20
21 23 reliance on both innate cytokines and T cell derived IL-2 for their activation, and thus tend to produce
22
23 24 less IFN-γ. Highly differentiated 'adaptive' NK cells ultimately become reliant on direct contact with
24
25 25 target cells or immune complexes for their activation and thus on cytotoxic mechanisms of action; in
26
27 26 the case of malaria infection this translates into an almost exclusive reliance on activation via CD16
28
29 27 and antigen-IgG immune complexes and thus on ADCC as the primary NK cell-mediated effector
30
31 28 mechanism.

32
33
34 29 Evidence from *in vitro* studies and from longitudinal studies of human malaria infection supports the
35
36 30 notion of a switch from innate cytokine/T cell-mediated NK cell activation towards protection
37
38 31 dependent on malaria-specific antibody-dependent NK cell responses ¹⁰. Early observations of
39
40 32 antibody-dependent NK cell activation in response to iRBC ¹⁰¹ have been confirmed by more recent
41
42 33 studies providing convincing evidence that antibodies to *P. falciparum* PfEMP-1 and RIFINs (both of
43
44 34 which are expressed at the surface of iRBC) can inhibit parasite replication and kill malaria-infected
45
46 35 erythrocytes *in vitro* in the presence of NK cells derived from malaria naïve individuals ¹⁰². Of note,
47
48 36 human anti-malarial antibodies belong almost exclusively to the IgG1 and IgG3 subclasses (the Fc
49
50 37 regions of which preferentially bind CD16) and have repeatedly been associated with protective
51
52 38 immunity to malaria ¹⁰³⁻¹⁰⁶. As ADCC is preferentially mediated by more differentiated
53
54 39 CD56^{dim}CD57+NKG2C+ and CD56^{dim}FcεR1γ-/PLZF- NK cells that accumulate with increasing age,
55
56 40 NK cell maturation in combination with gradual acquisition of antibodies to a broad repertoire of
57
58 41 PfEMP-1 and RIFIN serotypes may contribute to the well documented phenomenon of age- and
59
60 42

1
2
3 442 exposure-related acquisition of effective anti-malarial immunity. The almost universal exposure to
4
5 443 HCMV in sub-Saharan African populations, concomitant exposure to other pro-inflammatory
6
7 444 infections (potentially including malaria itself) ^{7,107-109} and the consequent rapid accumulation of
8
9 445 CD57+ NKG2C+ NK cells ³⁶ may accelerate this process. In support of this hypothesis, a recent
10
11 446 study in Malian children and young adults reported that peripheral blood frequencies of PLZF-
12
13 447 adaptive NK cells were positively associated with ADCC against *P. falciparum*-infected erythrocytes
14
15 448 and inversely correlated with parasite burden and probability of infection in the subsequent malaria
16
17 449 season ¹¹⁰.

23 24 451 **Cytokine-dependent NK activation after malaria vaccination**

25
26 452 The role of NK cells as effector cells of vaccine-induced protection has been proposed by ourselves
27
28 453 and others (reviewed in ¹¹¹). With regard to malaria, enhanced IFN- γ production by NK cells was
29
30 454 demonstrated after RTS,S vaccination and was correlated with vaccine antigen-specific IL-2
31
32 455 production ⁹². However, as described above, CHMI of RTS,S vaccinated individuals suggested an
33
34 456 inverse correlation between NK associated gene signatures and protection ⁹⁰, although this may
35
36 457 simply reflect tissue sequestration of activated NK cells during active infection. On a more positive
37
38 458 note, liver IL-12 and NK cell signatures were associated with protection in a *P. chabaudi* vaccination
39
40 459 and challenge study ^{112,113} and a *P. vivax* vaccination study reported increased NK cell frequencies
41
42 460 after vaccination ¹¹⁴.

48 49 462 **Concluding remarks: the multifaceted role of NK cells in malaria**

50
51 463 Observations from natural human infection, *in vitro* systems and animal models broadly support the
52
53 464 notion that NK cell responses to malaria in naïve or non-immune individuals are largely driven by
54
55 465 innate, pro-inflammatory cytokines induced principally by erythrocytic stages of *Plasmodium spp.*
56
57 466 We propose, therefore, that in malaria endemic populations, the gradual acquisition of acquired
58
59 467 immune responses (both memory T cells and specific antibodies) is mirrored by rapid differentiation

1
2
3
4 68 of NK cells and accumulation of adaptive NK cells with potent ADCC capability; the transition from
5
6 69 dependence on largely innate to largely adaptive NK cell-activating signals is smoothed by the ability
7
8 70 of intermediate differentiation stages of NK cells to interpolate both sets of signals, including T cell-
9
10 71 derived IL-2 . *Figure 3* shows a proposed model for the gradual evolution of the NK cell effector
11
12 72 response to malaria-infected erythrocytes over the life course of an individual. In this model, age
13
14 73 and exposure to HCMV and other pro-inflammatory infections (including malaria) leads to gradual
15
16 74 differentiation of the NK cell population from being reliant for its activation on malaria-induced
17
18 75 inflammatory cytokines towards increasing reliance on malaria antigen-antibody immune
19
20 76 complexes. At the same time, acquisition of immune regulatory mechanisms that moderate the
21
22 77 inflammatory cytokine response to malaria and the increasing diversity of the anti-malarial antibody
23
24 78 response enable NK cells to mediate very effective ADCC responses and to clear the infection with
25
26 79 minimal inflammation. If so, it should be possible to track this 'evolution' of the NK cell-mediated anti-
27
28 80 malarial immune response - both phenotypically and functionally – in malaria-exposed individuals to
29
30
31 81 reveal informative, composite correlates of protection against malaria infection and disease. At the
32
33 82 same time, the potential for anti-inflammatory cytokines (in particular IL-10 and TGF- β) to moderate
34
35 83 the function of less differentiated, cytokine-responsive and cytokine-producing NK cells should be
36
37 84 explored. In addition, given recent evidence from murine infection and vaccination models that NK
38
39 85 cells may inhibit affinity maturation of immunoglobulins by negatively regulating somatic
40
41 86 hypermutation in germinal centres ^{115,116}, it may be of value to correlate NK cell phenotype and
42
43 87 function with the affinity maturation of the anti-malarial antibody response.

44
45 88 There is abundant evidence that host genetic diversity contributes to resistance/susceptibility to
46
47 89 malaria and to variation in individual and population level NK cell responses to malaria parasites.
48
49
50 90 The interaction between polymorphic inhibitory KIR and HLA class I molecules helps to determine
51
52 91 the functional competence of NK cells ²⁹ and a number of studies have suggested an association
53
54 92 between KIR genotype and the severity of malaria disease ^{32,33,117,118}. At the same time,
55
56 93 polymorphisms in genes encoding cytokines and cytokine receptors ¹¹⁹⁻¹²¹ and immunoglobulin Fc
57
58 94 receptors including CD16 and CD32 ¹²²⁻¹²⁴ may affect the avidity of these interactions, the activation
59
60 95 of NK cells and – directly or indirectly – the outcome of malaria infections. Traits that influence NK

1
2
3
4 296 cell differentiation may also have functional consequences: for example a deletion variant of *NKG2C*,
5
6 497 present at high allele frequency in some African populations, is associated with delayed NK cell
7
8 498 differentiation ³⁶ and may have implications for the generation of effective ADCC responses to
9
10 499 malaria.

11
12 500 Lastly, differences in the functional and phenotypic characteristics of NK cells in the peripheral blood
13
14 501 and tissues may merit consideration. The relative over-representation of less differentiated NK cells
15
16 502 in secondary lymphoid organs and other tissues compared to peripheral blood, where highly
17
18 503 differentiated CD16+ and 'adaptive' NK cell types tend to accumulate, may mean that the entire NK
19
20 504 cell pool remains rather more diverse than might be apparent from the circulating NK cell population,
21
22 505 with important consequences for immunity to malaria and other infections. As our understanding of
23
24 506 the dynamic spectrum of NK cell differentiation and responsiveness during infection increases, we
25
26 507 may likewise better understand the role of innate lymphocytes during anti-malarial immunity and in
27
28 508 the evolution of natural protection against disease.
29

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

M.R.G. is supported by the Innovative Medicines Initiative 2 Joint Undertaking (Grant 115861).

This joint undertaking receives support from the Europeans Union’s Horizon 2020 Research and Innovation Programme and Association.

For Review Only

Figure Legends

Figure 1. Human NK cell differentiation and adaptation. CD56^{bright} NK cells express high levels of activating NCRs and cytokine receptors. As NK cells begin to differentiate, they begin to downregulate cytokine receptors and NCRs and to express CD16 and KIR. Highly differentiated NK cells express CD57, high levels of KIR and LIR-1, and may express CD94/NKG2C⁺ at high frequency. Adaptive NK cells, which are assumed to differentiate from CD56^{dim} (CD57⁻ or CD57⁺) NK cells lose expression of the FcεR1γ adaptor protein and the transcriptional regulator PLZF.

Figure 2. Activation of NK cells by malaria parasites. Myeloid cells (monocytes, macrophages and myeloid DCs) recognise soluble components of blood stage *Plasmodium spp* and phagocytose infected erythrocytes and extracellular parasites, leading to triggering of PRRs (including TLR4 and TLR9) and release of NK cell-activating pro-inflammatory cytokines. Myeloid cells also provide accessory signals to NK cells via cell surface receptors including adhesion molecules, leading to activation of NK cells and their secretion of IFN-γ. Plasmacytoid DC can additionally recognise parasite DNA (complexed to hemozoin or other parasite proteins) via TLR9-independent pathways, leading to type 1 interferon production and further activation of NK cells. Adapted from Newman and Riley ¹²⁵ ; symbols as in Figure 1.

Figure 3. Model for the co-evolution of adaptive NK cells and anti-malarial immunity. With increasing age and repeated malaria infections, children in malaria endemic areas gradually acquire adaptive (T cell and antibody) immunity. At the same time, their NK cells gradually differentiate from cytokine-activated/cytokine-producing cells to become specialised for ADCC. We propose, therefore that early in life (**panel A**) when antibodies are lacking, the NK cell response is driven by malaria-induced inflammation and NK cells secrete IFN-γ which enhances the phagocytic clearance of infected erythrocytes but may also contribute to inflammatory disease. With increasing age and malaria exposure (**panel B**), the acquisition of IL-2-producing memory T cells and anti-malarial antibodies

1
2
3 42 may enhance both cytokine-driven NK cell effector mechanisms and ADCC. In later life (**panel C**),
4
5 43 an increasing ability to modulate (or actively regulate) the inflammatory response to malaria,
6
7 44 combined with maturation of the anti-malarial antibody response and accumulation of “adaptive” NK
8
9 45 cells, results in control of infection via very effective ADCC with minimal inflammation. Cells and
10
11 46 symbols as shown in legend to Figures 1 and 2.

12
13
14 47
15
16
17 48
18
19 49
20
21 50
22
23 51
24
25 52
26
27 53
28
29
30 54
31
32
33 55
34
35
36 56
37
38 57
39
40
41 58
42
43
44 59
45
46
47 60
48
49
50 61
51
52 62
53
54
55 63
56
57
58 64
59
60
61 65

For Review Only

1
2
366
4
5
667 **References**
7
8

- 568 1. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in
10 antiviral defense: function and regulation by innate cytokines. *Annu Rev Immunol.*
569 1999;17:189-220.
12
570
14
571 2. Kiessling R, Bataillon G, Lamon EW, Klein E. The lymphocyte response to primary Moloney
16 sarcoma virus tumors: definition of a non-specific component of the in vitro cellular
572 hyporeactivity of tumor-bearing hosts. *Int J Cancer.* 1974;14(5):642-648.
18
573
20
574 3. Horowitz A, Strauss-Albee DM, Leipold M, et al. Genetic and environmental determinants of
22 human NK cell diversity revealed by mass cytometry. *Sci Transl Med.* 2013;5(208):208ra145.
23
575
24
25
576 4. Beziat V, Liu LL, Malmberg JA, et al. NK cell responses to cytomegalovirus infection lead to
27 stable imprints in the human KIR repertoire and involve activating KIRs. *Blood.*
577 2013;121(14):2678-2688.
29
578
31
579 5. Parham P, Guethlein LA. Genetics of Natural Killer Cells in Human Health, Disease, and
33 Survival. *Annu Rev Immunol.* 2018;36:519-548.
34
580
35
581 6. Juelke K, Killig M, Luetke-Eversloh M, et al. CD62L expression identifies a unique subset of
37 polyfunctional CD56dim NK cells. *Blood.* 2010;116(8):1299-1307.
38
582
39
583 7. Lee J, Zhang T, Hwang I, et al. Epigenetic modification and antibody-dependent expansion
41 of memory-like NK cells in human cytomegalovirus-infected individuals. *Immunity.*
42
584
43
44
585
45
46
586 8. Lopez-Verges S, Milush JM, Pandey S, et al. CD57 defines a functionally distinct population
48 of mature NK cells in the human CD56dimCD16+ NK-cell subset. *Blood.* 2010;116(19):3865-
49
50
588
51
52
589 9. Schlums H, Cichocki F, Tesi B, et al. Cytomegalovirus infection drives adaptive epigenetic
54 diversification of NK cells with altered signaling and effector function. *Immunity.*
55
590
56
591
57
58
59
60

- 1
2
3 92 10. Crompton PD, Moebius J, Portugal S, et al. Malaria immunity in man and mosquito: insights
4 into unsolved mysteries of a deadly infectious disease. *Annu Rev Immunol.* 2014;32:157-
5 93 187.
6
7 94
8
9 95 11. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than
10 answers. *Nat Immunol.* 2008;9(7):725-732.
11
12 96 12. Caligiuri MA. Human natural killer cells. *Blood.* 2008;112(3):461-469.
13
14 97 13. Nielsen CM, White MJ, Goodier MR, Riley EM. Functional Significance of CD57 Expression
15 on Human NK Cells and Relevance to Disease. *Front Immunol.* 2013;4:422.
16
17 98 14. Fali T, Papagno L, Bayard C, et al. New Insights into Lymphocyte Differentiation and Aging
18 from Telomere Length and Telomerase Activity Measurements. *J Immunol.*
19 2019;202(7):1962-1969.
20
21 99 15. Crinier A, Milpied P, Escaliere B, et al. High-Dimensional Single-Cell Analysis Identifies
22 Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice. *Immunity.*
23 2018;49(5):971-986 e975.
24
25 100 16. Fehniger TA, Bluman EM, Porter MM, et al. Potential mechanisms of human natural killer
26 cell expansion in vivo during low-dose IL-2 therapy. *J Clin Invest.* 2000;106(1):117-124.
27
28 101 17. Lee SH, Fragoso MF, Biron CA. Cutting edge: a novel mechanism bridging innate and
29 adaptive immunity: IL-12 induction of CD25 to form high-affinity IL-2 receptors on NK cells.
30 *J Immunol.* 2012;189(6):2712-2716.
31
32 102 18. Nielsen CM, Wolf AS, Goodier MR, Riley EM. Synergy between Common gamma Chain
33 Family Cytokines and IL-18 Potentiates Innate and Adaptive Pathways of NK Cell Activation.
34 *Front Immunol.* 2016;7:101.
35
36 103 19. White MJ, Nielsen CM, McGregor RH, Riley EH, Goodier MR. Differential activation of CD57-
37 defined natural killer cell subsets during recall responses to vaccine antigens. *Immunology.*
38 2014;142(1):140-150.
39
40 104 20. Bar-On Y, Charpak-Amikam Y, Glasner A, et al. NKp46 Recognizes the Sigma1 Protein of
41 Reovirus: Implications for Reovirus-Based Cancer Therapy. *J Virol.* 2017;91(19).
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 21. Narni-Mancinelli E, Gauthier L, Baratin M, et al. Complement factor P is a ligand for the
5
6 20 natural killer cell-activating receptor NKp46. *Sci Immunol.* 2017;2(10).
7
8 22. Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent DC maturation is mediated by
9
10 TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor.
11
12 *Blood.* 2005;106(2):566-571.
13
14 23. Walwyn-Brown K, Guldevall K, Saeed M, et al. Human NK Cells Lyse Th2-Polarizing
15
16 Dendritic Cells via NKp30 and DNAM-1. *J Immunol.* 2018;201(7):2028-2041.
17
18 24. Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The Broad Spectrum of Human Natural
19
20 Killer Cell Diversity. *Immunity.* 2017;47(5):820-833.
21
22 25. Ferlazzo G, Pack M, Thomas D, et al. Distinct roles of IL-12 and IL-15 in human natural killer
23
24 cell activation by dendritic cells from secondary lymphoid organs. *Proc Natl Acad Sci U S A.*
25
26 2004;101(47):16606-16611.
27
28 26. Ferlazzo G, Thomas D, Lin SL, et al. The abundant NK cells in human secondary lymphoid
29
30 tissues require activation to express killer cell Ig-like receptors and become cytolytic. *J*
31
32 *Immunol.* 2004;172(3):1455-1462.
33
34 27. Marquardt N, Beziat V, Nystrom S, et al. Cutting edge: identification and characterization of
35
36 human intrahepatic CD49a+ NK cells. *J Immunol.* 2015;194(6):2467-2471.
37
38 28. Goodridge JP, Onfelt B, Malmberg KJ. Newtonian cell interactions shape natural killer cell
39
40 education. *Immunol Rev.* 2015;267(1):197-213.
41
42 29. Hoglund P, Brodin P. Current perspectives of natural killer cell education by MHC class I
43
44 molecules. *Nat Rev Immunol.* 2010;10(10):724-734.
45
46 30. Liu LL, Landskron J, Ask EH, et al. Critical Role of CD2 Co-stimulation in Adaptive Natural
47
48 Killer Cell Responses Revealed in NKG2C-Deficient Humans. *Cell Rep.* 2016;15(5):1088-
49
50 1099.
51
52 31. Goodridge JP, Jacobs B, Saetersmoen ML, et al. Remodeling of secretory lysosomes during
53
54 education tunes functional potential in NK cells. *Nat Commun.* 2019;10(1):514.
55
56
57
58
59
60

- 1
2
3
4 32. Hirayasu K, Ohashi J, Kashiwase K, et al. Significant association of KIR2DL3-HLA-C1
5
6 combination with cerebral malaria and implications for co-evolution of KIR and HLA. *PLoS*
7
8 *Pathog.* 2012;8(3):e1002565.
- 9
10 33. Prakash S, Ranjan P, Ghoshal U, Agrawal S. KIR-like activating natural killer cell receptors
11
12 and their association with complicated malaria in north India. *Acta Trop.* 2018;178:55-60.
- 13
14 34. Junqueira C, Barbosa CRR, Costa PAC, et al. Cytotoxic CD8(+) T cells recognize and kill
15
16 *Plasmodium vivax*-infected reticulocytes. *Nat Med.* 2018;24(9):1330-1336.
- 17
18 35. Bjorkstrom NK, Riese P, Heuts F, et al. Expression patterns of NKG2A, KIR, and CD57 define
19
20 a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. *Blood.*
21
22 2010;116(19):3853-3864.
- 23
24 36. Goodier MR, White MJ, Darboe A, et al. Rapid NK cell differentiation in a population with
25
26 near-universal human cytomegalovirus infection is attenuated by NKG2C deletions. *Blood.*
27
28 2014;124(14):2213-2222.
- 29
30 37. Della Chiesa M, Falco M, Bertaina A, et al. Human cytomegalovirus infection promotes rapid
31
32 maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted
33
34 with NKG2C-/- umbilical cord blood. *J Immunol.* 2014;192(4):1471-1479.
- 35
36 38. Hammer Q, Ruckert T, Borst EM, et al. Peptide-specific recognition of human
37
38 cytomegalovirus strains controls adaptive natural killer cells. *Nat Immunol.* 2018;19(5):453-
39
40 463.
- 41
42 39. Hammer Q, Ruckert T, Dunst J, Romagnani C. Adaptive Natural Killer Cells Integrate
43
44 Interleukin-18 during Target-Cell Encounter. *Front Immunol.* 2017;8:1976.
- 45
46 40. Kalantari P. The Emerging Role of Pattern Recognition Receptors in the Pathogenesis of
47
48 Malaria. *Vaccines (Basel).* 2018;6(1).
- 49
50 41. Baratin M, Roetynck S, Lepolard C, et al. Natural killer cell and macrophage cooperation in
51
52 MyD88-dependent innate responses to *Plasmodium falciparum*. *Proc Natl Acad Sci U S A.*
53
54 2005;102(41):14747-14752. doi: 14710.11073/pnas.0507355102. Epub 0507352005 Oct
55
56 0507355103.
- 57
58
59
60

- 1
2
3 42. Gowda NM, Wu X, Gowda DC. TLR9 and MyD88 are crucial for the development of
4 protective immunity to malaria. *J Immunol.* 2012;188(10):5073-5085.
5
6 43. Gowda NM, Wu X, Kumar S, Febbraio M, Gowda DC. CD36 contributes to malaria parasite-
7 induced pro-inflammatory cytokine production and NK and T cell activation by dendritic cells.
8
9
10
11
12 44. Spaulding E, Fooksman D, Moore JM, et al. STING-Licensed Macrophages Prime Type I
13 IFN Production by Plasmacytoid Dendritic Cells in the Bone Marrow during Severe
14
15
16
17
18
19
20 45. Wu X, Gowda NM, Kumar S, Gowda DC. Protein-DNA complex is the exclusive malaria
21 parasite component that activates dendritic cells and triggers innate immune responses. *J*
22
23
24
25
26 46. Sharma S, DeOliveira RB, Kalantari P, et al. Innate immune recognition of an AT-rich stem-
27 loop DNA motif in the Plasmodium falciparum genome. *Immunity.* 2011;35(2):194-207.
28
29
30
31 47. Kalantari P, DeOliveira RB, Chan J, et al. Dual engagement of the NLRP3 and AIM2
32 inflammasomes by plasmodium-derived hemozoin and DNA during malaria. *Cell Rep.*
33
34
35
36
37 48. Parroche P, Lauw FN, Goutagny N, et al. Malaria hemozoin is immunologically inert but
38 radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. *Proc*
39
40
41
42
43 49. Hirako IC, Gallego-Marin C, Ataide MA, et al. DNA-Containing Immunocomplexes Promote
44 Inflammasome Assembly and Release of Pyrogenic Cytokines by CD14⁺ CD16⁺ CD64^{high}
45
46
47
48
49
50 50. Artavanis-Tsakonas K, Riley EM. Innate Immune Response to Malaria: Rapid Induction of
51 IFN- from Human NK Cells by Live Plasmodium falciparum-Infected Erythrocytes. *The*
52
53
54
55
56 51. Newman KC, Korbel DS, Hafalla JC, Riley EM. Cross-talk with myeloid accessory cells
57 regulates human natural killer cell interferon-gamma responses to malaria. *PLoS Pathog.*
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

52. Baratin M, Roetync S, Pouvelle B, et al. Dissection of the role of PfEMP1 and ICAM-1 in the sensing of Plasmodium-falciparum-infected erythrocytes by natural killer cells. *PLoS One*. 2007;2(2):e228.
53. Korbel DS, Newman KC, Almeida CR, Davis DM, Riley EM. Heterogeneous Human NK Cell Responses to Plasmodium falciparum-Infected Erythrocytes. *The Journal of Immunology*. 2005;175(11):7466-7473.
54. Horowitz A, Newman KC, Evans JH, Korbel DS, Davis DM, Riley EM. Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes. *J Immunol*. 2010;184(11):6043-6052.
55. Artavanis-Tsakonas K, Eleme K, McQueen KL, et al. Activation of a Subset of Human NK Cells upon Contact with Plasmodium falciparum-Infected Erythrocytes. *The Journal of Immunology*. 2003;171(10):5396-5405.
56. Grangeiro de Carvalho E, Bonin M, Kremsner PG, Kun JF. Plasmodium falciparum-infected erythrocytes and IL-12/IL-18 induce diverse transcriptomes in human NK cells: IFN-alpha/beta pathway versus TREM signaling. *PLoS One*. 2011;6(9):e24963.
57. Delahaye NF, Barbier M, Fumoux F, Rihet P. Association analyses of NCR3 polymorphisms with P. falciparum mild malaria. *Microbes Infect*. 2007;9(2):160-166.
58. Mavoungou E, Held J, Mewono L, Kremsner PG. A Duffy binding-like domain is involved in the NKp30-mediated recognition of Plasmodium falciparum-parasitized erythrocytes by natural killer cells. *J Infect Dis*. 2007;195(10):1521-1531.
59. Ye W, Chew M, Hou J, et al. Microvesicles from malaria-infected red blood cells activate natural killer cells via MDA5 pathway. *PLoS Pathog*. 2018;14(10):e1007298.
60. Saito F, Hirayasu K, Satoh T, et al. Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors. *Nature*. 2017;552(7683):101-105.
61. Eugui EM, Allison AC. Malaria infections in different strains of mice and their correlation with natural killer activity. *Bull World Health Organ*. 1979;57 Suppl 1:231-238.

- 1
2
3 26 62. Eugui EM, Allison AC. Differences in susceptibility of various mouse strains to
4
5 27 haemoprotozoan infections: possible correlation with natural killer activity. *Parasite Immunol.*
6
7 28 1980;2(4):277-292.
- 9 29 63. Mohan K, Moulin P, Stevenson MM. Natural killer cell cytokine production, not cytotoxicity,
10
11 30 contributes to resistance against blood-stage *Plasmodium chabaudi* AS infection. *J Immunol.*
12
13 31 1997;159(10):4990-4998.
- 15 32 64. Su Z, Stevenson MM. IL-12 Is Required for Antibody-Mediated Protective Immunity Against
16
17 33 Blood-Stage *Plasmodium chabaudi* AS Malaria Infection in Mice. *The Journal of*
18
19 34 *Immunology.* 2002;168(3):1348-1355.
- 21 35 65. Ing R, Gros P, Stevenson MM. Interleukin-15 enhances innate and adaptive immune
22
23 36 responses to blood-stage malaria infection in mice. *Infect Immun.* 2005;73(5):3172-3177.
- 24 37 66. Ing R, Stevenson MM. Dendritic cell and NK cell reciprocal cross talk promotes gamma
25
26 38 interferon-dependent immunity to blood-stage *Plasmodium chabaudi* AS infection in mice.
27
28 39 *Infect Immun.* 2009;77(2):770-782.
- 30 40 67. Kim CC, Parikh S, Sun JC, et al. Experimental malaria infection triggers early expansion of
31
32 41 natural killer cells. *Infect Immun.* 2008;76(12):5873-5882.
- 34 42 68. Muxel SM, Freitas do Rosario AP, Sardinha LR, et al. Comparative analysis of activation
35
36 43 phenotype, proliferation, and IFN-gamma production by spleen NK1.1(+) and NK1.1(-) T
37
38 44 cells during *Plasmodium chabaudi* AS malaria. *J Interferon Cytokine Res.* 2010;30(6):417-
39
40 45 426.
- 41 46 69. Stegmann KA, De Souza JB, Riley EM. IL-18-induced expression of high-affinity IL-2R on
42
43 47 murine NK cells is essential for NK-cell IFN-gamma production during murine *Plasmodium*
44
45 48 *yoelii* infection. *Eur J Immunol.* 2015;45(12):3431-3440.
- 49 49 70. Thylur RP, Wu X, Gowda NM, et al. CD36 receptor regulates malaria-induced immune
50
51 50 responses primarily at early blood stage infection contributing to parasitemia control and
52
53 51 resistance to mortality. *J Biol Chem.* 2017;292(22):9394-9408.
54
55 52
56
57
58
59
60

- 1
2
3 752 71. Ryg-Cornejo V, Nie CQ, Bernard NJ, et al. NK cells and conventional dendritic cells engage
4 in reciprocal activation for the induction of inflammatory responses during Plasmodium
5 753 berghei ANKA infection. *Immunobiology*. 2013;218(2):263-271.
6
7 754
8
9 755 72. Hansen DS, Ryg-Cornejo V, Ioannidis LJ, et al. The contribution of natural killer complex loci
10 to the development of experimental cerebral malaria. *PLoS One*. 2014;9(4):e93268.
11
12 756
13 757 73. Adachi K, Tsutsui H, Kashiwamura SI, et al. Plasmodium berghei Infection in Mice Induces
14 Liver Injury by an IL-12- and Toll-Like Receptor/Myeloid Differentiation Factor 88-Dependent
15
16 758 Mechanism. *The Journal of Immunology*. 2001;167(10):5928-5934.
17
18 759
19 760 74. Tamura T, Akbari M, Kimura K, Kimura D, Yui K. Flt3 ligand treatment modulates parasitemia
20 during infection with rodent malaria parasites via MyD88- and IFN-gamma-dependent
21
22 761 mechanisms. *Parasite Immunol*. 2014;36(2):87-99.
23
24 762
25 763 75. Burrack KS, Huggins MA, Taras E, et al. Interleukin-15 Complex Treatment Protects Mice
26 from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells. *Immunity*.
27
28 764 2018;48(4):760-772 e764.
29
30 765
31 766 76. Morosan S, Hez-Deroubaix S, Lunel F, et al. Liver-stage development of Plasmodium
32 falciparum, in a humanized mouse model. *J Infect Dis*. 2006;193(7):996-1004. doi:
33
34 767 1010.1086/500840. Epub 502006 Feb 500828.
35
36 768
37 769 77. Arnold L, Tyagi RK, Mejia P, Van Rooijen N, Perignon JL, Druilhe P. Analysis of innate
38 defences against Plasmodium falciparum in immunodeficient mice. *Malar J*. 2010;9:197.
39
40 770
41 771 78. Chen Q, Amaladoss A, Ye W, et al. Human natural killer cells control Plasmodium falciparum
42 infection by eliminating infected red blood cells. *Proc Natl Acad Sci U S A*. 2014;111(4):1479-
43
44 772 1484.
45
46 773
47
48 774 79. Wolf AS, Sherratt S, Riley EM. NK Cells: Uncertain Allies against Malaria. *Front Immunol*.
49 2017;8:212.
50
51 775
52 776 80. Doodoo D, Omer FM, Todd J, Akanmori BD, Koram KA, Riley EM. Absolute levels and ratios
53 of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical
54
55 777 immunity to Plasmodium falciparum malaria. *J Infect Dis*. 2002;185(7):971-979. doi:
56
57 778 910.1086/339408. Epub 332002 Mar 339411.
58
59 779
60

- 1
2
3 80 81. Chaiyaroj SC, Rutta ASM, Muenthaisong K, Watkins P, Na Ubol M, Looareesuwan S.
4
5 81 Reduced levels of transforming growth factor- β 1, interleukin-12 and increased migration
6
7 82 inhibitory factor are associated with severe malaria. *Acta Tropica*. 2004;89(3):319-327.
8
9 83 82. Lyke KE, Burges R, Cissoko Y, et al. Serum levels of the proinflammatory cytokines
10
11 84 interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in
12
13 85 Malian children with severe Plasmodium falciparum malaria and matched uncomplicated
14
15 86 malaria or healthy controls. *Infect Immun*. 2004;72(10):5630-5637.
16
17 87 83. Mandala WL, Msefula CL, Gondwe EN, et al. Lymphocyte Perturbations in Malawian
18
19 88 Children with Severe and Uncomplicated Malaria. *Clin Vaccine Immunol*. 2015;23(2):95-103.
20
21 89 84. Ayimba E, Hegewald J, Segbena AY, et al. Proinflammatory and regulatory cytokines and
22
23 90 chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria. *Clin*
24
25 91 *Exp Immunol*. 2011;166(2):218-226.
26
27 92 85. Mandala WL, Msefula CL, Gondwe EN, Drayson MT, Molyneux ME, MacLennan CA.
28
29 93 Cytokine Profiles in Malawian Children Presenting with Uncomplicated Malaria, Severe
30
31 94 Malarial Anemia, and Cerebral Malaria. *Clin Vaccine Immunol*. 2017;24(4).
32
33 95 86. McCall MB, Roestenberg M, Ploemen I, et al. Memory-like IFN-gamma response by NK cells
34
35 96 following malaria infection reveals the crucial role of T cells in NK cell activation by P.
36
37 97 falciparum. *Eur J Immunol*. 2010;40(12):3472-3477.
38
39 98 87. Teirlinck AC, McCall MB, Roestenberg M, et al. Longevity and composition of cellular
40
41 99 immune responses following experimental Plasmodium falciparum malaria infection in
42
43 800 humans. *PLoS Pathog*. 2011;7(12):e1002389.
44
45 801 88. Ng SS, Souza-Fonseca-Guimaraes F, Rivera FL, et al. Rapid loss of group 1 innate lymphoid
46
47 802 cells during blood stage Plasmodium infection. *Clin Transl Immunology*. 2018;7(1):e1003.
48
49 803 89. Hviid L, Kurtzhals JA, Goka BQ, Oliver-Commey JO, Nkrumah FK, Theander TG. Rapid
50
51 804 reemergence of T cells into peripheral circulation following treatment of severe and
52
53 805 uncomplicated Plasmodium falciparum malaria. *Infect Immun*. 1997;65(10):4090-4093.
54
55 806 90. Kazmin D, Nakaya HI, Lee EK, et al. Systems analysis of protective immune responses to
56
57 807 RTS,S malaria vaccination in humans. *Proc Natl Acad Sci U S A*. 2017;114(9):2425-2430.

- 1
2
308 91. Mpina M, Maurice NJ, Yajima M, et al. Controlled Human Malaria Infection Leads to Long-
4 Lasting Changes in Innate and Innate-like Lymphocyte Populations. *J Immunol.*
509 2017;199(1):107-118.
6
7
810
9
811 92. Horowitz A, Hafalla JC, King E, et al. Antigen-specific IL-2 secretion correlates with NK cell
11 responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine.
812 *J Immunol.* 2012;188(10):5054-5062.
13
813
15
814 93. Goodier MR, Rodriguez-Galan A, Lusa C, et al. Influenza Vaccination Generates Cytokine-
17 Induced Memory-like NK Cells: Impact of Human Cytomegalovirus Infection. *J Immunol.*
815 2016;197(1):313-325.
19
816
21
817 94. Horowitz A, Behrens RH, Okell L, Fooks AR, Riley EM. NK cells as effectors of acquired
23 immune responses: effector CD4+ T cell-dependent activation of NK cells following
818 vaccination. *J Immunol.* 2010;185(5):2808-2818.
25
26
819
27
28
820 95. Nielsen CM, White MJ, Bottomley C, et al. Impaired NK Cell Responses to Pertussis and
29 H1N1 Influenza Vaccine Antigens in Human Cytomegalovirus-Infected Individuals. *J*
30
821 *Immunol.* 2015;194(10):4657-4667.
32
822
34
823 96. Costa-Garcia M, Vera A, Moraru M, Vilches C, Lopez-Botet M, Muntasell A. Antibody-
36 mediated response of NKG2Cbright NK cells against human cytomegalovirus. *J Immunol.*
824 2015;194(6):2715-2724.
38
825
40
826 97. Goodier MR, Lusa C, Sherratt S, Rodriguez-Galan A, Behrens R, Riley EM. Sustained
42 Immune Complex-Mediated Reduction in CD16 Expression after Vaccination Regulates NK
827 Cell Function. *Front Immunol.* 2016;7:384.
44
828
45
829 98. Gooneratne SL, Richard J, Lee WS, Finzi A, Kent SJ, Parsons MS. Slaying the Trojan horse:
48 natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytotoxicity
49 against allogeneic T cells. *J Virol.* 2015;89(1):97-109.
50
51
831
53
832 99. Vandervan HA, Jegaskanda S, Wines BD, et al. Antibody-Dependent Cellular Cytotoxicity
55 Responses to Seasonal Influenza Vaccination in Older Adults. *J Infect Dis.* 2017;217(1):12-
57
833 23.
59
834
60

- 1
2
335 100. Marquardt N, Ivarsson MA, Blom K, et al. The Human NK Cell Response to Yellow Fever
4
536 Virus 17D Is Primarily Governed by NK Cell Differentiation Independently of NK Cell
6
737 Education. *J Immunol.* 2015;195(7):3262-3272.
8
938 101. Mavoungou E, Luty AJ, Kremsner PG. Natural killer (NK) cell-mediated cytotoxicity of
10
11 Plasmodium falciparum-infected human red blood cells in vitro. *Eur Cytokine Netw.*
12
13 2003;14(3):134-142.
14
15 102. Arora G, Hart GT, Manzella-Lapeira J, et al. NK cells inhibit Plasmodium falciparum growth
16
17 in red blood cells via antibody-dependent cellular cytotoxicity. *Elife.* 2018;7.
18
19 103. Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to Plasmodium falciparum
20
21 merozoite surface protein 2 (MSP2): increasing prevalence with age and association with
22
23 clinical immunity to malaria. *Am J Trop Med Hyg.* 1998;58(4):406-413.
24
25 104. Stanistic DI, Fowkes FJ, Koinari M, et al. Acquisition of antibodies against Plasmodium
26
27 falciparum merozoites and malaria immunity in young children and the influence of age, force
28
29 of infection, and magnitude of response. *Infect Immun.* 2015;83(2):646-660.
30
31 105. Stanistic DI, Richards JS, McCallum FJ, et al. Immunoglobulin G subclass-specific responses
32
33 against Plasmodium falciparum merozoite antigens are associated with control of
34
35 parasitemia and protection from symptomatic illness. *Infect Immun.* 2009;77(3):1165-1174.
36
37 106. Dechavanne C, Sadissou I, Bouraima A, et al. Acquisition of natural humoral immunity to P.
38
39 falciparum in early life in Benin: impact of clinical, environmental and host factors. *Sci Rep.*
40
41 2016;6:33961.
42
43 107. Bjorkstrom NK, Lindgren T, Stoltz M, et al. Rapid expansion and long-term persistence of
44
45 elevated NK cell numbers in humans infected with hantavirus. *J Exp Med.* 2011;208(1):13-
46
47 21.
48
49 108. Petitdemange C, Becquart P, Wauquier N, et al. Unconventional repertoire profile is
50
51 imprinted during acute chikungunya infection for natural killer cells polarization toward
52
53 cytotoxicity. *PLoS Pathog.* 2011;7(9):e1002268.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

109. Saghafian-Hedengren S, Sohlberg E, Theorell J, et al. Epstein-Barr virus coinfection in children boosts cytomegalovirus-induced differentiation of natural killer cells. *J Virol*. 2013;87(24):13446-13455.
110. Hart GT, Tran TM, Theorell J, et al. Adaptive NK cells in people exposed to *Plasmodium falciparum* correlate with protection from malaria. *J Exp Med*. 2019.
111. Wagstaffe HR, Mooney JP, Riley EM, Goodier MR. Vaccinating for natural killer cell effector functions. *Clin Transl Immunology*. 2018;7(1):e1010.
112. Al-Quraishy S, Dkhil MA, Abdel-Baki AAS, Delic D, Wunderlich F. Protective vaccination alters gene expression of the liver of Balb/c mice in response to early prepatent blood-stage malaria of *Plasmodium chabaudi*. *Parasitol Res*. 2018;117(4):1115-1129.
113. Al-Quraishy S, Dkhil MA, Al-Shaebi EM, et al. Gene expression of the liver of vaccination-protected mice in response to early patent infections of *Plasmodium chabaudi* blood-stage malaria. *Malar J*. 2018;17(1):215.
114. Kwon MH, Kim HH, Lee HS, et al. *Plasmodium vivax*: comparison of the immune responses between oral and parenteral immunization of rPv54 in BALB/c mice. *Exp Parasitol*. 2010;126(2):217-223.
115. Rydyznski C, Daniels KA, Karmele EP, et al. Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells. *Nat Commun*. 2015;6:6375.
116. Rydyznski CE, Cranert SA, Zhou JQ, et al. Affinity Maturation Is Impaired by Natural Killer Cell Suppression of Germinal Centers. *Cell Rep*. 2018;24(13):3367-3373 e3364.
117. Norman PJ, Hollenbach JA, Nemat-Gorgani N, et al. Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans. *PLoS Genet*. 2013;9(10):e1003938.
118. Yindom LM, Forbes R, Aka P, et al. Killer-cell immunoglobulin-like receptors and malaria caused by *Plasmodium falciparum* in The Gambia. *Tissue Antigens*. 2012;79(2):104-113.
119. Dhangadamajhi G, Kar A, Rout R, Dhangadamajhi P. A meta-analysis of TLR4 and TLR9 SNPs implicated in severe malaria. *Rev Soc Bras Med Trop*. 2017;50(2):153-160.

- 1
2
388 120. Leoratti FM, Farias L, Alves FP, et al. Variants in the toll-like receptor signaling pathway and
4 clinical outcomes of malaria. *J Infect Dis.* 2008;198(5):772-780.
589
6
7
890 121. Sam-Agudu NA, Greene JA, Opoka RO, et al. TLR9 polymorphisms are associated with
8 altered IFN-gamma levels in children with cerebral malaria. *Am J Trop Med Hyg.*
9
10
11
12 2010;82(4):548-555.
13
14
15 122. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-
16 158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa,
17 independently of the Fc gammaRIIIa-48L/R/H phenotype. *Blood.* 1997;90(3):1109-1114.
18
19
20
21 123. Oboshi W, Watanabe T, Matsuyama Y, et al. The influence of NK cell-mediated ADCC:
22 Structure and expression of the CD16 molecule differ among Fc gammaRIIIa-V158F
23 genotypes in healthy Japanese subjects. *Hum Immunol.* 2016;77(2):165-171.
24
25
26
27 124. Cherif M, Amoako-Sakyi D, Dolo A, et al. Distribution of Fc gamma R gene polymorphisms
28 among two sympatric populations in Mali: differing allele frequencies, associations with
29 malarimetric indices and implications for genetic susceptibility to malaria. *Malar J.*
30
31
32
33 2016;15:29.
34
35
36 125. Newman KC, Riley EM. Whatever turns you on: accessory-cell-dependent activation of NK
37 cells by pathogens. *Nat Rev Immunol.* 2007;7(4):279-291.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

179x143mm (300 x 300 DPI)




Figure 2

80x36mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3

180x120mm (300 x 300 DPI)